Our results highlighted inhibition of PTGR2 as a new effective approach to prevent obesity, improve insulin sensitivity and insulin tolerance, and reduce hepatic steatosis without adverse side effects through increasing endogenous PPARγ ligands. The gene discussed is PPARG; the disease is obesity due to melanocortin 4 receptor deficiency.